Literature DB >> 11422020

Public health impact of adverse bone effects of oral corticosteroids.

T P van Staa1, L Abenhaim, C Cooper, B Zhang, H G Leufkens.   

Abstract

AIMS: The objective of this study was to estimate the number of fractures attributed to oral corticosteroid use.
METHODS: Information was obtained from the General Practice Research Database which contains medical records of general practitioners in the UK. The total number of corticosteroid-related fractures during a course of treatment was estimated using the formula for attributable risk among the exposed.
RESULTS: A total of 244 235 patients was prescribed an oral corticosteroid. The rate of hip fractures increased exponentially with age in both males and females. The excess number of hip fracture cases among females aged 85 years or older using 7.5 mg prednisolone per day or more was 1.4 cases per 100 patients per year. About 47% of all hip and 72% of all vertebral fractures that occurred can be attributed to oral corticosteroid use. Among 10 000 female users of higher doses, 99.7 nonvertebral, 31.6 hip and 45.8 vertebral fractures can be attributed to use of oral corticosteroids.
CONCLUSIONS: The targeting of high-risk patients will be important for implementing preventative strategies in a cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422020      PMCID: PMC2014495          DOI: 10.1046/j.0306-5251.2001.1385.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  The UK General Practice Research Database.

Authors:  T Walley; A Mantgani
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

2.  Some insights into Miettinen's multivariate confounder score approach to case-control study analysis.

Authors:  M C Pike; J Anderson; N Day
Journal:  J Epidemiol Community Health       Date:  1979-03       Impact factor: 3.710

3.  The VAMP Research multi-purpose database in the U.K.

Authors:  Y Lis; R D Mann
Journal:  J Clin Epidemiol       Date:  1995-03       Impact factor: 6.437

4.  Public health methods--attributable risk as a link between causality and public health action.

Authors:  M E Northridge
Journal:  Am J Public Health       Date:  1995-09       Impact factor: 9.308

5.  Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

Authors:  C Roux; P Oriente; R Laan; R A Hughes; J Ittner; S Goemaere; O Di Munno; J M Pouillès; S Horlait; B Cortet
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

Review 6.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

7.  Pre-existing fractures and bone mass predict vertebral fracture incidence in women.

Authors:  P D Ross; J W Davis; R S Epstein; R D Wasnich
Journal:  Ann Intern Med       Date:  1991-06-01       Impact factor: 25.391

8.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

Authors:  K G Saag; R Koehnke; J R Caldwell; R Brasington; L F Burmeister; B Zimmerman; J A Kohler; D E Furst
Journal:  Am J Med       Date:  1994-02       Impact factor: 4.965

9.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

10.  The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results.

Authors:  T P Van Staa; L Abenhaim; C Cooper; B Zhang; H G Leufkens
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-09       Impact factor: 2.890

View more
  18 in total

1.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids.

Authors:  J A Kanis; H Johansson; A Oden; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-01-13       Impact factor: 4.507

Review 2.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

3.  Survey of short-term oral corticosteroid administration by orthopaedic physicians in college and high school athletes.

Authors:  Sudhakar G Madanagopal; John E Kovaleski; Albert W Pearsall
Journal:  J Sports Sci Med       Date:  2009-03-01       Impact factor: 2.988

Review 4.  Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.

Authors:  Margaret Gourlay; Nora Franceschini; Yevgeniy Sheyn
Journal:  Clin Rheumatol       Date:  2006-05-03       Impact factor: 2.980

5.  Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study.

Authors:  T Card; J West; R Hubbard; R F A Logan
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

6.  Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients.

Authors:  A L Dolan; E Koshy; M Waker; C M Goble
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

7.  Fractures of the proximal femur: correlates of radiological evidence of osteoporosis.

Authors:  Salil H Patel; Kieran P Murphy
Journal:  Skeletal Radiol       Date:  2006-02-10       Impact factor: 2.199

Review 8.  Disease risk score as a confounder summary method: systematic review and recommendations.

Authors:  Mina Tadrous; Joshua J Gagne; Til Stürmer; Suzanne M Cadarette
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-11-21       Impact factor: 2.890

9.  Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2009-11-19

Review 10.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.